Arno Therapeutics (ARNI) 0.5900 $ARNI
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that Chief Operating Officer, Lawrence Kenyon, is scheduled to present at the Noble Financial Capital Markets' 11 Annual Equity Conference, being held January 18-21, 2015 at Club Med in Sandpiper Bay, FL.
Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
GlobeNewswire - Wed Dec 10, 8:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that it has dosed the first patient in the Phase II component of a modified Phase I/II clinical study evaluating its lead compound onapristone in women with progesterone receptor expressing tumors. The Phase II study will include up to 29 patients with recurrent or metastatic endometrioid tumors that have been shown to express the activated progesterone receptor (APR), and who have received no more than one prior chemotherapy and no prior hormone therapy.
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
GlobeNewswire - Tue Dec 09, 8:11AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that data from a study supporting diagnostic development for its lead compound onapristone will be presented at a poster session at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held December 9-13, 2014 in San Antonio, Texas. The symposium is hosted by The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Sciences Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine.
Arno Therapeutics announces changes in board
M2 - Fri Dec 05, 4:26AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) reported on Thursday that it has named Dr Alexander Zukiwski, MD as a member of its board of directors and chief executive officer.
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors
GlobeNewswire - Thu Dec 04, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that it has appointed Alexander Zukiwski, M.D. to its Board of Directors. The Board of Directors also appointed Dr. Zukiwski as the Company's Chief Executive Officer. Dr. Zukiwski, who had served as the Company's Interim CEO since July 2014, will also continue in his role as Arno's Chief Medical Officer.
Arno Therapeutics to Present at LD Micro Conference 2014
GlobeNewswire - Mon Nov 24, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Alex Zukiwski, M.D., is scheduled to present at the Annual LD Micro Conference, being held December 2-4, 2014 at the Luxe Hotel in Los Angeles, CA.
Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update
GlobeNewswire - Fri Nov 14, 3:35PM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the third quarter of 2014 and provided an update on recent clinical developments for its lead compound, onapristone.
Arno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference
GlobeNewswire - Wed Oct 29, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected to present at the 5 Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference, being held October 27-29, 2014 in Alexandria, Va.
Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has advanced its Phase I clinical trial evaluating its lead compound onapristone in women with progesterone receptor expressing tumors to the expansion stage and has now begun enrolling patients at the recommended Phase II dose of 50mg extended release tablets twice daily. This dose has been determined by an independent safety review committee to be safe and is the single agent dose which will be used in future clinical studies. The expansion stage of the Phase I study will include approximately 24 patients and is expected to primarily enroll patients with gynecologic tumors (including endometrial, ovarian and other uterine tumors) who have received fewer prior chemotherapy regimens than the patients enrolled in the dose escalation stage of the study.
Arno Therapeutics to Present Encouraging Data From Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat
GlobeNewswire - Thu Oct 23, 7:34AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it will present data from its ongoing Phase I/II clinical trial (NCT02049190) evaluating investigational lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide at the 21 Annual Prostate Cancer Foundation (PCF) Scientific Retreat, being held October 23-25, 2014 at the La Costa Hotel in Carlsbad, California.
Arno Therapeutics to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Dr. Alex Zukiwski is scheduled to present at the 13 Annual BIO Investor Forum, being held October 7-8, 2014 at The Palace Hotel in San Francisco, CA.
Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014
GlobeNewswire - Thu Sep 18, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected as Chair of World CDx Boston 2014, the 5 annual summit of this meeting, being held September 23-25, 2014 in Boston, Mass.
Arno Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Dr. Alex Zukiwski, Chief Executive Officer and Mr. Lawrence Kenyon, Chief Financial Officer, are scheduled to present at the 16 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2014 in New York and the Aegis Capital 2014 Healthcare & Technology Conference being held September 10-13, 2014 in Las Vegas.
Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
GlobeNewswire - Thu Aug 14, 3:49PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the second quarter of 2014 and provided an update on recent clinical developments.
Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
GlobeNewswire - Fri Jul 18, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, M.D., has been appointed as the interim Chief Executive Officer effective immediately. Dr. Zukiwski will continue in his role as Vice President and Chief Medical Officer of the Company. Dr. Zukiwski has an extensive background in pharmaceuticals and biotechnology over a distinguished 19 year career, including serving as Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc., as well as positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech. Dr. Zukiwski replaces Mr. Glenn Mattes, who is leaving to pursue other opportunities.
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that Chief Operating Officer, Lawrence Kenyon, is scheduled to present at the Noble Financial Capital Markets' 11 Annual Equity Conference, being held January 18-21, 2015 at Club Med in Sandpiper Bay, FL.
Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
GlobeNewswire - Wed Dec 10, 8:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that it has dosed the first patient in the Phase II component of a modified Phase I/II clinical study evaluating its lead compound onapristone in women with progesterone receptor expressing tumors. The Phase II study will include up to 29 patients with recurrent or metastatic endometrioid tumors that have been shown to express the activated progesterone receptor (APR), and who have received no more than one prior chemotherapy and no prior hormone therapy.
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
GlobeNewswire - Tue Dec 09, 8:11AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that data from a study supporting diagnostic development for its lead compound onapristone will be presented at a poster session at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held December 9-13, 2014 in San Antonio, Texas. The symposium is hosted by The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Sciences Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine.
Arno Therapeutics announces changes in board
M2 - Fri Dec 05, 4:26AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) reported on Thursday that it has named Dr Alexander Zukiwski, MD as a member of its board of directors and chief executive officer.
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors
GlobeNewswire - Thu Dec 04, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that it has appointed Alexander Zukiwski, M.D. to its Board of Directors. The Board of Directors also appointed Dr. Zukiwski as the Company's Chief Executive Officer. Dr. Zukiwski, who had served as the Company's Interim CEO since July 2014, will also continue in his role as Arno's Chief Medical Officer.
Arno Therapeutics to Present at LD Micro Conference 2014
GlobeNewswire - Mon Nov 24, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Alex Zukiwski, M.D., is scheduled to present at the Annual LD Micro Conference, being held December 2-4, 2014 at the Luxe Hotel in Los Angeles, CA.
Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update
GlobeNewswire - Fri Nov 14, 3:35PM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the third quarter of 2014 and provided an update on recent clinical developments for its lead compound, onapristone.
Arno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference
GlobeNewswire - Wed Oct 29, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected to present at the 5 Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference, being held October 27-29, 2014 in Alexandria, Va.
Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has advanced its Phase I clinical trial evaluating its lead compound onapristone in women with progesterone receptor expressing tumors to the expansion stage and has now begun enrolling patients at the recommended Phase II dose of 50mg extended release tablets twice daily. This dose has been determined by an independent safety review committee to be safe and is the single agent dose which will be used in future clinical studies. The expansion stage of the Phase I study will include approximately 24 patients and is expected to primarily enroll patients with gynecologic tumors (including endometrial, ovarian and other uterine tumors) who have received fewer prior chemotherapy regimens than the patients enrolled in the dose escalation stage of the study.
Arno Therapeutics to Present Encouraging Data From Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat
GlobeNewswire - Thu Oct 23, 7:34AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it will present data from its ongoing Phase I/II clinical trial (NCT02049190) evaluating investigational lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide at the 21 Annual Prostate Cancer Foundation (PCF) Scientific Retreat, being held October 23-25, 2014 at the La Costa Hotel in Carlsbad, California.
Arno Therapeutics to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Dr. Alex Zukiwski is scheduled to present at the 13 Annual BIO Investor Forum, being held October 7-8, 2014 at The Palace Hotel in San Francisco, CA.
Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014
GlobeNewswire - Thu Sep 18, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected as Chair of World CDx Boston 2014, the 5 annual summit of this meeting, being held September 23-25, 2014 in Boston, Mass.
Arno Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Dr. Alex Zukiwski, Chief Executive Officer and Mr. Lawrence Kenyon, Chief Financial Officer, are scheduled to present at the 16 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2014 in New York and the Aegis Capital 2014 Healthcare & Technology Conference being held September 10-13, 2014 in Las Vegas.
Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
GlobeNewswire - Thu Aug 14, 3:49PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the second quarter of 2014 and provided an update on recent clinical developments.
Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
GlobeNewswire - Fri Jul 18, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, M.D., has been appointed as the interim Chief Executive Officer effective immediately. Dr. Zukiwski will continue in his role as Vice President and Chief Medical Officer of the Company. Dr. Zukiwski has an extensive background in pharmaceuticals and biotechnology over a distinguished 19 year career, including serving as Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc., as well as positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech. Dr. Zukiwski replaces Mr. Glenn Mattes, who is leaving to pursue other opportunities.
